2019
Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis
ANDRAŠINA, Tomáš, Michal UHER, Tomáš ROHAN, Peter MATKULČÍK, Jan ZAVADIL et. al.Základní údaje
Originální název
Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis
Autoři
ANDRAŠINA, Tomáš (703 Slovensko, domácí), Michal UHER (203 Česká republika), Tomáš ROHAN (203 Česká republika, domácí), Peter MATKULČÍK (703 Slovensko, domácí), Jan ZAVADIL (203 Česká republika, domácí), Barbora ČECHOVÁ (203 Česká republika, domácí), Lujza JANDUROVÁ (703 Slovensko, domácí) a Vlastimil VÁLEK (203 Česká republika, domácí)
Vydání
CIRSE 2019, 2019
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Obor
30224 Radiology, nuclear medicine and medical imaging
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.034
Kód RIV
RIV/00216224:14110/19:00110836
Organizační jednotka
Lékařská fakulta
ISSN
Klíčová slova anglicky
hepatocellular carcinoma; transarterial chemoembolisation; survival analysis
Štítky
Příznaky
Mezinárodní význam
Změněno: 16. 4. 2020 08:19, Mgr. Tereza Miškechová
Anotace
V originále
Purpose: To evaluate survival beneft in patient undergoing transarterial chemoembolization for hepatocellular carcinoma by national registry data analysis and comparison of regions with unequal usage of interventional radiology procedures. Material and methods: 4343 patients with primary diagnosis of HCC between 2010-2016 were extracted from the databases of The Czech National Cancer Registry. The analysis was supported by data from the National Registry of Paid Health Services and the Death Records Database. Primary treatment option was categorized as liver resection, ablation, TACE and chemotherapy. The regional data analysis provided information of IR procedures frequency for primary treatment of HCC. The 14 main regions were symmetrically divided to group with welldeveloped IR service and low-developed IR service according to the frequency of stage-adjusted IR procedure usage (<15%,>15%). Kaplan-Meier and Cox regression were used for survival and hazard ratios analyses. Results: Only 1730 patients had assessed any primary treatment option, 16.5% (285) were treated by TACE. Median of survival were signifcantly diferent in regions with well and low developed IR service for whole study population (13.2 months vs 6.5, p< 0.001), patients treated in regions with well developed IR service had lower risk of death during treatment (HR=0.73 (0.66-0.81). The patient treated by TACE had median of survival 15.8 months (13.5-18.1), while the survival was not signifcantly diferent in region groups. Conclusion: The usage of anticancer therapies based on IR procedures is a huge factor infuencing the survival of HCC patient according to population-based data. Studies gathering data from cancer register databases can provide further information on treatment efectiveness.
Návaznosti
| MUNI/A/0996/2018, interní kód MU |
| ||
| MUNI/A/1574/2018, interní kód MU |
|